Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s65. https://doi.org/10.25251/skin.6.supp.65